Peer-to-Peer Review in Prior Authorization: Clinical Conversation, Coverage Process, and the Limits of Informal Reconsideration

Why peer-to-peer review has become a policy issue

Prior authorization is often described as a paperwork process, but many contested decisions turn on clinical interpretation. A plan may believe that a requested MRI does not meet criteria, that a biologic has not satisfied step requirements, that an inpatient level of care is unsupported, or that a procedure is not medically necessary under the governing benefit standard. The treating clinician may believe the submitted documentation fails to capture an important nuance, or that the payer's reviewer has applied the wrong criterion. Peer-to-peer review developed as one way to put clinicians in direct conversation before or after a denial.

The phrase sounds reassuring because it suggests equality: one physician speaking with another physician about a patient's care. The actual process can be more complicated. The plan reviewer may not share the treating physician's specialty. The call may be scheduled after a denial or before one. The reviewer may have authority to reverse the decision, recommend reconsideration, or only explain criteria. The plan may call the conversation “peer-to-peer,” “medical director review,” “clinical reconsideration,” or another term. In some workflows the treating physician has only a narrow window to request the call.

Those differences matter because a clinician may mistakenly believe that participating in a peer-to-peer discussion automatically preserves the patient's formal appeal rights. It may not. A plan may also describe a call as an opportunity for “discussion” when the practical purpose is to complete information that should have been requested earlier. Conversely, a treating physician may approach the call as an argument about the desirability of treatment when the actual coverage question is whether a specific contractual or regulatory criterion is satisfied.

The policy objective should therefore be clarity. Peer-to-peer review is potentially valuable, but it should not become an opaque parallel system in which coverage decisions change without an auditable record or formal rights expire while clinicians wait for an informal call.

1. What peer-to-peer review is—and is not

At its core, a peer-to-peer review is a direct clinical discussion between a treating or requesting clinician and a clinician working for or on behalf of a payer or utilization-management organization. The purpose is usually to discuss the clinical basis of a request or adverse decision. The label does not itself tell us the legal status of the conversation.

It is not necessarily an independent review. The plan's reviewer remains part of the plan's utilization-management system or its contractor. It is not necessarily an appeal because the plan may classify the call as pre-denial clarification, post-denial reconsideration, or an informal opportunity outside the formal grievance process. It is not necessarily “peer” in the sense of identical specialty, practice setting, or experience. And it is not necessarily a final decision point.

A policy analysis should therefore begin with four questions: who is participating; when the call occurs; what authority the reviewer has; and what happens procedurally after the call. A conversation before an initial decision serves a different function from a discussion after an adverse benefit determination. A discussion in which the reviewer can approve the request is different from one in which the reviewer can only recommend that another unit reopen the case.

Physicians should also distinguish the peer-to-peer process from a request to speak with a medical director merely to understand a decision. Both may be useful, but only the payer's governing documents and applicable law reveal whether the interaction changes the status of the claim or authorization.

2. The clinical value of direct conversation

Structured criteria cannot always capture the full clinical context in the initial submission. A request form may ask whether physical therapy was attempted but not explain why physical therapy was contraindicated. A utilization-management system may register that a medication failed without capturing the adverse reaction that makes rechallenge unreasonable. A diagnosis code may be too broad to communicate the clinical phenotype that drives the treatment recommendation.

Peer-to-peer discussion can close those gaps quickly. The treating clinician can explain sequence, severity, comorbidity, prior treatment, response, contraindication, urgency, or the consequences of delay. The payer's reviewer can identify the exact criterion that appears unsatisfied. If the problem is truly incomplete information, the discussion may allow the record to be corrected without a prolonged appeal.

The benefit is greatest when both clinicians have access to the same governing criteria and enough of the clinical record to discuss the issue meaningfully. A call is less useful when the plan reviewer cannot identify the standard being applied, when the treating physician has not reviewed the denial reason, or when the discussion is limited to repeating a scripted conclusion.

Direct conversation can also reveal that the dispute is not actually clinical. The service may be excluded from the benefit, the provider may be out of network, the authorization may have been submitted to the wrong entity, or the requested billing code may not match the clinical service. A physician-to-physician call cannot solve every administrative defect, and forcing clinicians to spend time on nonclinical problems is itself a form of administrative waste.

3. Specific denial reasons change the conversation

CMS-0057-F requires impacted payers to provide a specific reason for denied prior-authorization requests for covered non-drug items and services under the rule's scope. The rule also requires standardized Prior Authorization APIs beginning generally in 2027 and public reporting of specified prior-authorization metrics beginning in 2026. CMS, Prior Authorization API FAQ

A specific reason is essential to meaningful peer-to-peer review. “Not medically necessary” is a legal category, but by itself it may not tell the treating physician whether the problem was missing imaging, duration of conservative therapy, an age criterion, a diagnosis mismatch, failure of a preferred treatment, a site-of-service rule, or a conclusion that the expected benefit does not justify the requested intervention.

The more precise the denial reason, the more focused the discussion can be. A well-functioning system should permit the treating clinician to see the criterion before the call and should identify the particular element that is disputed. That reduces the incentive to treat peer-to-peer review as a negotiation in which approval depends on rhetorical persistence rather than evidence.

Specific reasons also make quality measurement possible. A plan can examine whether denials are commonly reversed because the initial reviewer misapplied criteria, because provider submissions are incomplete, because electronic documentation requirements are poorly designed, or because the criteria themselves generate avoidable disputes. Without structured reason data, “peer-to-peer success rates” can be difficult to interpret.

4. The Medicare Advantage context

Medicare Advantage is a particularly important context because CMS has codified utilization-management protections that shape, but do not eliminate, plan-level peer-to-peer workflows. CMS has clarified that Medicare Advantage organizations must use applicable Traditional Medicare coverage criteria when those criteria are established and has restricted how plans may develop and use internal coverage criteria. Plans also must maintain utilization-management committees that review utilization-management policies. CMS, 2024 Medicare Advantage and Part D Final Rule (CMS-4201-F)

These rules mean that a peer-to-peer conversation should not be treated as free-form bargaining over whether the payer is willing to cover care. The reviewer should be able to identify the applicable Medicare coverage standard, plan criterion, or other lawful basis for the decision. If internal criteria are being used, their permissible role depends on the Medicare Advantage framework.

CMS has also established continuity protections for prior authorization. A prior authorization for a course of treatment must remain valid for as long as medically reasonable and necessary under applicable criteria, the patient's medical history, and the treating provider's recommendation. New Medicare Advantage enrollees undergoing an active course of treatment also receive transition protections under the applicable rules. Those protections can matter more than whether a plan offers an informal peer-to-peer call.

The practical lesson is to identify the formal right first. Peer-to-peer discussion can complement Medicare Advantage protections, but it should not obscure them. If the dispute concerns an appealable organization determination, the patient and provider should know the applicable appeal route and deadline independently of the call.

5. Specialty matching and reviewer expertise

The term “peer” can imply that the plan reviewer has the same specialty as the requesting physician. That is not a universal rule. Reviewer qualification requirements vary by program, state, decision type, and stage of review. Some processes require appropriate clinical expertise; others permit a physician in a related field; still others involve pharmacists or different licensed professionals for certain services.

From a quality perspective, exact specialty matching is most important when the decision depends on specialized judgment that a general reviewer may not reasonably possess. A complex oncology regimen, rare-disease therapy, subspecialty surgical indication, or unusual pediatric condition may warrant a reviewer with directly relevant expertise. Routine criteria-based decisions may not require an identical subspecialty.

The correct policy question is not “same specialty or no review.” It is whether the reviewer has sufficient knowledge and experience to evaluate the disputed clinical issue. Plans should have an escalation mechanism when the initial reviewer recognizes that the case exceeds that expertise.

Transparency would improve trust. The treating physician should at least know the reviewer's professional discipline and, where relevant, specialty. Credential details need not become a vehicle for harassment, but anonymous authority undermines a process that relies on professional judgment.

6. Timing can determine whether the process helps or harms

A peer-to-peer opportunity offered after a critical deadline may be practically useless. Similarly, a call scheduled days later in an urgent case may create avoidable clinical risk even if the formal authorization deadline has not yet expired. The correct timing depends on the patient's condition and the governing program.

CMS-0057-F requires impacted payers within its operational scope to issue decisions within 72 hours for expedited prior-authorization requests and seven calendar days for standard requests. The deadline is a maximum; other program rules may require action as expeditiously as the patient's condition requires. CMS, Prior Authorization API FAQ

Peer-to-peer scheduling should operate inside those timeframes rather than becoming a reason to reset them casually. If the payer requests more information, the effect on timing depends on the governing rule. The plan should state clearly whether the case is still pending, formally denied, administratively closed, or reopened.

For physicians, the safest operational rule is to track both clocks: the clinical clock and the procedural clock. What happens to the patient if care is delayed? And what is the deadline to request reconsideration, appeal, external review, or another remedy? A helpful peer-to-peer conversation should not require sacrificing either.

7. Peer-to-peer review should not erase the written record

Telephone conversations create a documentation problem. The participants may remember the discussion differently. A reviewer may approve a service verbally but the authorization system may not update. A treating physician may submit new information during the call that never appears in the formal file. A later appeal reviewer may see only the original denial.

Every peer-to-peer process should generate a basic written record: date and time, participants, the clinical issue, criteria discussed, additional facts or records provided, whether the decision changed, the authorization number if approved, any conditions or duration limits, and the next procedural step if the denial remains.

The treating organization should keep its own contemporaneous note. The note need not be argumentative. It should identify what was discussed and what the payer represented. If the payer requests additional documentation, the physician's team should send it through a channel that produces confirmation of receipt.

This documentation protects both sides. It allows the payer to audit reviewer consistency and permits the provider to distinguish a true clinical disagreement from a system failure. It also gives journalists and regulators a more reliable basis for studying how often peer-to-peer review changes decisions and why.

8. Informal reconsideration and formal appeal are different

One of the most important distinctions in prior-authorization administration is between a plan's internal convenience process and a legally recognized appeal. Peer-to-peer review may occur before an adverse determination, after a denial but before a formal appeal, or as part of a reconsideration process. The nomenclature differs across plans.

The patient should not lose formal rights merely because the physician pursued an informal route. Unless the plan or governing law clearly states otherwise, the treating team should not assume that a peer-to-peer request extends an appeal deadline. If both processes can proceed, the provider may need to preserve the appeal while attempting clinical reconsideration.

This distinction also affects who controls the process. A physician may initiate a peer-to-peer call, but formal appeal rights often belong to the member, an authorized representative, or a provider acting under specified authorization. A plan cannot use provider-to-provider discussion as a substitute for required member notice and appeal instructions.

Policy documents should say this plainly. A clinician should not need legal training to discover whether accepting a peer-to-peer appointment on Tuesday causes an appeal deadline to expire on Monday.

9. What the treating physician should prepare

The most effective peer-to-peer calls are targeted. Before the call, the physician should identify the exact requested service, denial reason, governing criterion, and missing or disputed element. Repeating the entire medical history wastes time and may obscure the point.

A concise preparation sheet can include diagnosis, severity, relevant objective findings, prior treatment, dates and outcomes, contraindications, the requested service, why alternatives are inadequate, the expected clinical benefit, and the harm of delay. If the request is urgent, the physician should articulate the factual reason the standard timeframe is unsafe rather than simply label the case “urgent.”

The physician should have the actual denial notice available. Staff summaries can omit important language. If the plan cites a policy or coverage guideline, the physician should obtain it before the discussion where possible.

The goal is not to “win” through forcefulness. It is to make the record answer the criterion. When the physician believes the criterion itself is inconsistent with governing coverage law or current evidence, that issue should be preserved for formal review rather than reduced to a personality contest with the plan reviewer.

10. What the plan reviewer should bring

The reviewer should know which criterion governs, what information was considered, and what precise element remains unsatisfied. The reviewer should also have authority appropriate to the purpose of the call. If the reviewer cannot change the decision, that limitation should be disclosed at the outset.

The reviewer should distinguish plan policy from law. “Our policy says so” is not a complete explanation when federal or state requirements constrain the policy. Likewise, “Medicare requires it” should be used only when the cited Medicare authority actually does.

A good reviewer listens for new facts rather than simply defending the initial decision. Utilization management should function as decision-making, not adversarial advocacy. When new information satisfies the criterion, the process should permit an efficient correction.

The reviewer should also avoid practicing medicine for the patient. A coverage reviewer can explain what the plan covers and why; the reviewer should be cautious about directing a substitute treatment without full clinical responsibility for the patient. If an alternative is mentioned, it should be framed as a coverage option that the treating clinician must assess clinically.

11. Reversal rates are difficult to interpret

A high rate of approvals after peer-to-peer review can be presented as evidence that the process works. It can also suggest that the initial process generates avoidable denials. A low reversal rate can mean initial decisions are accurate, or that peer-to-peer review is too constrained to change them.

Without denominator and reason data, the metric is ambiguous. How many requests were denied initially? How many qualified for peer-to-peer review? How many clinicians requested it? How many calls were completed? How many decisions changed? Were changes based on new evidence or correction of an initial error? How many cases later succeeded on appeal?

CMS's public prior-authorization metrics under CMS-0057-F represent an important transparency step, but they do not answer every question about peer-to-peer review. Plans and policymakers could improve accountability by reporting optional metrics that distinguish initial denial, additional-information requests, informal reconsideration, peer-to-peer outcomes, appeals, and final disposition.

Journalists should be especially skeptical of a statistic such as “95 percent of peer-to-peer reviews resolved the issue.” Resolved how? Approval, alternative service, abandonment, or confirmation of denial? The numerator needs a definition.

12. Algorithmic screening makes human review more important—not less

Automation can identify missing documentation, apply rule-based criteria, route cases, and support prior-authorization workflows. The policy question is what happens when automated or algorithm-supported processing produces an adverse result or flags a case for denial.

Human review should not consist merely of clicking through the machine's conclusion. The clinician reviewer should be able to see the evidence, understand the criterion, recognize exceptions, consider individualized clinical context, and depart from an automated recommendation when warranted. Otherwise, the peer-to-peer conversation becomes performative: a human is present, but the decision is effectively fixed upstream.

Plans should document which parts of the process are automated and which are clinically adjudicated. This does not require disclosure of every proprietary algorithmic detail, but accountability requires enough information to know whether the adverse decision resulted from a coverage rule, a predictive model, a documentation check, or a clinician's judgment.

The treating physician should also be able to identify whether new information can change the outcome. If the model simply reruns the same rule after each upload, a live discussion may be the only opportunity to expose a mismatch between structured data and actual clinical circumstances.

13. Peer-to-peer review can create inequity

A process that depends heavily on clinician persistence may advantage organizations with dedicated authorization teams, protected administrative time, and staff who understand each payer's informal rules. Small practices, safety-net clinics, and clinicians serving high-volume populations may not have the same capacity to wait on hold, schedule calls, repeat submissions, or escalate decisions.

Patients can therefore experience different access to the same covered service based on the administrative infrastructure of the treating practice rather than their clinical need. This is a policy concern even when every individual denial technically follows a criterion.

Electronic prior authorization may reduce some burden by making coverage requirements and documentation needs more visible earlier in the workflow. CMS's 2027 API requirements are intended in part to support that goal. But APIs do not eliminate the need for human judgment when criteria are ambiguous or the patient falls outside the common pathway. CMS, Electronic Prior Authorization

Equity analysis should therefore examine not only approval rates but administrative effort required to achieve an approval. Time spent by physicians and staff is a real resource, and its distribution affects access.

14. The call can clarify medical necessity without deciding medical truth

“Medical necessity” is both a clinical phrase and a coverage term. The treating physician may believe a treatment is medically indicated. The plan may apply a contractual, statutory, or regulatory definition of covered medical necessity. Those concepts overlap but are not identical.

Peer-to-peer review is useful when it makes that distinction explicit. The plan reviewer should identify the coverage criterion; the treating physician should explain why the patient's facts satisfy it or why an exception applies. The discussion should not imply that denial proves the treatment is medically inappropriate.

Conversely, a treating physician's recommendation does not automatically establish coverage. Benefit exclusions, network rules, noncovered services, or lawful coverage standards may limit payment even when treatment is clinically reasonable.

This distinction is particularly important for public communication. A denial is a coverage determination. It may involve clinical judgment, but it is not the same as a second treating opinion delivered with full responsibility for the patient's care.

15. Urgent cases require a different operational posture

When delay could seriously jeopardize life, health, or the ability to regain maximum function under an applicable expedited-review standard, the process should move at the urgent pace required by law and clinical circumstance. A peer-to-peer scheduling queue designed for routine cases should not control an urgent one.

The treating physician should document the consequence of delay specifically. “Patient is in pain” may be true but may not communicate why waiting is medically dangerous. “Delay risks progression of spinal cord compression with new motor deficit” provides a clinically meaningful basis for urgency.

Plans should have rapid reviewer availability for urgent cases and a process to bypass routine scheduling bottlenecks. If a peer-to-peer call cannot occur within the decision timeframe, the plan still remains responsible for meeting the governing deadline.

Emergency services are governed by separate coverage protections and should not be delayed merely to obtain routine prior authorization. Clinicians should not use peer-to-peer review as a substitute for emergency care when the patient requires immediate evaluation or treatment.

16. Pharmacy-benefit peer-to-peer review can operate under different rules

CMS-0057-F's core prior-authorization API and timing framework focuses on non-drug items and services. Prescription drugs are governed by other frameworks, including Medicare Part D, state pharmacy-benefit rules, Medicaid requirements, formularies, and plan contracts. In April 2026, CMS proposed broader interoperability and prior-authorization requirements for drugs, but those proposals remain proposals unless and until finalized. CMS-0062-P Fact Sheet

A physician discussing a drug denial should therefore identify whether the request concerns formulary status, step therapy, quantity limits, a nonformulary exception, prior authorization, or another restriction. The appeal and expedited-review rules may differ from a medical-benefit service.

The “peer” may also be a pharmacist depending on the decision and governing law. That can be entirely appropriate for medication-use criteria. The relevant question remains whether the reviewer has suitable expertise and authority for the issue.

Articles and plan materials should avoid presenting the 72-hour and seven-day CMS-0057-F non-drug deadlines as universal drug-authorization deadlines.

17. California adds another layer

California-regulated health plans and insurers are subject to state utilization-review, grievance, and independent-review requirements that can apply differently from federal programs and self-funded employer plans. Determining the regulator is therefore an early step.

A DMHC-regulated plan, a CDI-regulated insurance product, Medicare Advantage, Medi-Cal managed care, and a self-funded ERISA plan may all use the phrase “peer-to-peer review” while operating under different legal structures. The insurance card's branding does not always reveal the governing regulator because insurers and administrators can serve several product types.

Physicians should know whether a state grievance or Independent Medical Review path may be available and when internal review must be exhausted. The existence of peer-to-peer review does not erase those rights.

California considered a more specific statutory peer-to-peer framework in Assembly Bill 510 during the 2025–2026 session. The bill would have created a defined peer-to-peer right and deadlines after specified medical-necessity decisions, but it did not become law; the California Legislature’s current bill-status record lists AB 510 as “Assembly — Died — Appropriations.” It therefore should not be cited as a current California entitlement. California AB 510

Current California law instead supplies other concrete utilization-review protections. Health and Safety Code section 1367.01 requires medical-necessity denials or modifications to be made by a licensed physician or other competent licensed health professional, requires written reasons and criteria, and requires denial communications to identify the responsible health professional with a direct telephone number or extension. Those rules can make clinician-to-reviewer communication possible, but they are not the same as the un-enacted AB 510 peer-to-peer procedure. California HSC § 1367.01

For health systems, payer-specific playbooks should therefore identify the plan type and regulatory route rather than merely list a telephone number for “P2P.”

18. What a fair process should disclose

A fair peer-to-peer program should provide the requesting clinician with enough information to prepare intelligently. At minimum, the plan should identify the service under review, denial or pending reason, criterion applied, documentation considered, deadline for the call, and what authority the reviewer has.

After the call, the plan should communicate the result in writing. If the decision remains adverse, the formal notice should contain the required appeal information. If the service is approved, the authorization should specify scope, duration, units, provider or facility constraints where applicable, and any other condition necessary to avoid later claim confusion.

The reviewer should not rely on undisclosed criteria that the treating clinician has no meaningful opportunity to address. Where law permits internal coverage criteria, transparency requirements should be followed.

These disclosures transform peer-to-peer review from an informal favor into a reproducible administrative process.

19. A model peer-to-peer workflow

A high-functioning workflow can be organized as follows:

1. The plan receives a complete authorization request.
2. Automated systems may check eligibility, completeness, and obvious criteria, but adverse clinical decisions requiring professional judgment receive appropriate human review.
3. If information is missing, the plan identifies the missing element specifically rather than issuing an ambiguous denial when a request for information is appropriate.
4. If an adverse clinical determination is contemplated or issued, the treating clinician receives the criterion and the precise reason.
5. A peer-to-peer opportunity is offered when it can meaningfully resolve a clinical dispute.
6. The treating clinician receives a realistic scheduling window that does not undermine statutory deadlines.
7. The reviewer has access to the relevant record and authority to act or clearly states the limit of authority.
8. New information is incorporated into the record.
9. The outcome is documented.
10. Formal appeal rights and deadlines are preserved and communicated independently.
11. The plan analyzes peer-to-peer data for recurring system failures.

This model is not mandated identically across all payers. It reflects the elements needed for transparency and useful clinical review.

20. Questions physicians should ask before the call

• What is the exact reason for the denial or pending issue?
• Which criterion was applied?
• Can I obtain the criterion in writing before the call?
• What information did the reviewer consider?
• Is this peer-to-peer discussion pre-denial, reconsideration, or part of an appeal?
• Does requesting or completing the call change the appeal deadline?
• What specialty or discipline is the reviewer?
• Can the reviewer approve the request during the call?
• If not, who can?
• May I submit additional records, and how will receipt be confirmed?
• What urgent-review standard applies?
• If the decision remains adverse, what is the next formal review step?

The answers should be documented when possible.

21. Questions plans and policymakers should ask

• How often are initial denials reversed after peer-to-peer review?
• What proportion of reversals result from new evidence versus initial reviewer error?
• How long do clinicians wait to schedule and complete calls?
• Do small practices complete peer-to-peer review at lower rates than large systems?
• Are specialists matched appropriately to complex cases?
• Does the process preserve formal appeal rights automatically, or does the plan clearly warn when it does not?
• Are algorithm-supported adverse decisions meaningfully reviewed by clinicians?
• How often does peer-to-peer review address nonclinical administrative defects that could have been resolved by staff?
• Are urgent cases escalated fast enough?
• Are outcomes documented in a form available to the patient and treating team?

A plan can comply with formal rules and still operate a wasteful peer-to-peer process. Administrative quality deserves its own measurement.

22. What journalists should ask when a payer highlights peer-to-peer access

A payer may describe peer-to-peer review as proof that physicians can resolve disputed decisions. Reporters should ask for denominator data. How many denials were eligible? How many physicians requested calls? How many calls were completed? How long did they take? How many decisions changed? What happened to patients whose clinicians did not complete the process?

Ask whether peer-to-peer review is available before or after denial and whether it tolls appeal deadlines. Ask how reviewer specialty is determined. Ask whether the plan uses automated tools to recommend or initiate denials and what authority the human reviewer has to depart from those tools.

Reporters should also distinguish plan marketing from regulatory requirements. A “24-hour peer-to-peer line” is not equivalent to a legal 24-hour decision deadline. A plan's median call completion time does not measure total elapsed time from the original authorization request.

Finally, ask whether approval after peer-to-peer review is counted as an initial approval or as an overturned denial in public metrics. Definitions can change the apparent performance dramatically.

23. Peer-to-peer review should become less common for preventable disputes

The best peer-to-peer review is not necessarily the one that handles the most calls. A mature prior-authorization system should reduce the number of disputes that require physician telephone time.

Coverage requirements discovery, structured documentation, electronic submission, and specific denial reasons can move information earlier in the process. CMS's 2027 API framework is designed to make covered-item requirements, documentation needs, and electronic requests more interoperable for impacted payers. CMS-0057-F

If an electronic system tells the clinician at order entry which documents are required, an avoidable denial for missing documentation should become less common. If the patient's facts genuinely raise a complex judgment question, peer-to-peer review remains valuable.

The policy goal is therefore not to eliminate clinician conversation. It is to reserve clinician conversation for questions that actually require clinician judgment.

24. The central principle

Peer-to-peer review is best understood as a potentially useful clinical communication mechanism embedded within a larger coverage system. Its legitimacy comes from improving the accuracy and efficiency of decisions, not from its name.

A useful process identifies the governing criterion, gives both clinicians access to the relevant facts, uses reviewers with appropriate expertise, documents the outcome, respects urgent clinical needs, and preserves formal rights. A poor process turns physicians into unpaid appeals staff, obscures deadlines, and makes access depend on persistence.

The distinction between clinical conversation and legal procedure should remain visible throughout. A peer-to-peer call can change a decision. It cannot, by itself, define the patient's entire appeal rights or prove that a denial was clinically correct.

25. The administrative-cost question belongs in the analysis

Peer-to-peer review consumes clinician time on both sides. The treating physician may leave clinic, reschedule patients, wait for a callback, repeat information already contained in the chart, and coordinate staff follow-up after the call. The plan pays for medical-director or reviewer time and for the infrastructure needed to schedule, record, and implement the outcome. Those costs do not prove that the process is wasteful; some disputes genuinely deserve direct clinical discussion. They do mean that a plan should know why the call was necessary.

A useful quality program classifies peer-to-peer encounters by cause. Was the original request incomplete? If so, could the electronic workflow have identified the missing field before submission? Was the correct documentation present but overlooked? Did the initial reviewer apply the wrong criterion? Was the case clinically unusual and therefore not suited to automated or first-level review? Did the plan's own policy contain an ambiguity? Different causes require different fixes.

The distinction matters when organizations calculate “burden.” Counting calls alone is crude. Ten difficult oncology cases requiring thoughtful specialist discussion may represent a well-targeted system. One hundred calls generated because a portal cannot ingest a common operative note may represent a design failure. The appropriate denominator is the volume and type of requests, not simply the number of conversations.

Provider organizations should perform the same analysis internally. Recurrent denials from one payer may reflect payer behavior, but they may also expose a local documentation problem, inconsistent coding, a failure to attach required studies, or confusion about the plan's network. A joint improvement process can remove preventable work without compromising appeal rights.

The best metric is therefore not the elimination of all peer-to-peer review. It is the proportion of peer-to-peer work that addresses genuinely irreducible clinical uncertainty rather than defects that technology, clearer criteria, or better documentation could have prevented.

26. Prior authorization approval does not guarantee payment

A successful peer-to-peer call can produce an authorization, but authorization and claim payment are not identical events. Payment may still depend on eligibility on the date of service, network status, the authorized provider and facility, billing code, units, timing, coordination of benefits, claim submission, and other plan rules. The plan should not communicate approval in a way that implies all later payment conditions have disappeared.

The treating organization should verify the authorization details immediately after the call. Which service was approved? Which code or code family? How many visits or units? Which site? Which clinician? What is the effective period? Does the authorization cover related services such as anesthesia, imaging guidance, implantable devices, or postoperative care? When those details are unclear, the apparent victory of a peer-to-peer call can be followed by a claim dispute that neither clinician expected.

The opposite error is also important. Care delivered without a required authorization does not automatically mean that the patient owes the entire charge. Provider contracts, state law, emergency protections, notice requirements, plan terms, and responsibility for obtaining authorization can affect whether the provider may bill the patient. A physician discussing the clinical merits of care should not make unsupported financial promises during the peer-to-peer conversation.

Plans can reduce downstream disputes by integrating authorization records with claims systems and by returning structured approval data through electronic workflows. The 2027 Prior Authorization API requirement is important partly because it creates a standardized channel for communicating approval, denial, expiration, and requests for more information. Technology will not eliminate coverage disputes, but it can reduce the number caused by missing or inconsistent authorization data.

27. A governance checklist for peer-to-peer programs

Organizations designing or auditing peer-to-peer review should ask whether the process would remain defensible if every step were visible to a patient, regulator, physician organization, and journalist. That test encourages explicit rules rather than informal customs.

A mature program should define eligibility for peer-to-peer review; distinguish pre-denial clarification from post-denial reconsideration; state the scheduling window; identify reviewer qualification rules; disclose whether the reviewer can reverse the decision; establish urgent escalation; protect formal appeal deadlines; record new evidence; produce a written outcome; and analyze aggregate results. It should also specify how conflicts of interest are handled and how complaints about reviewer conduct can be escalated.

Plans should periodically sample cases in which peer-to-peer review changed the outcome. The purpose is not to punish initial reviewers for reasonable disagreements. It is to discover patterns: criteria that are being misread, documentation that is repeatedly missed, specialties that require better reviewer matching, or automated logic that produces false negatives. Cases in which the decision did not change should also be sampled for delay, clarity, and fairness.

Provider systems can mirror this governance. They can track which specialties spend the most time on peer-to-peer calls, which payers generate the highest burden, how often calls reverse decisions, and whether patients experience treatment delay. Data should be normalized for service volume and case mix before public conclusions are drawn.

Finally, governance should include a route for eliminating unnecessary peer-to-peer requirements. When a dispute category can be resolved reliably through structured data, published coverage rules, or a corrected electronic workflow, the system should retire the call rather than preserve it simply because “that is how prior authorization has always been done.” Clinical conversation is valuable enough that it should not be wasted on avoidable administrative defects.

28. When peer-to-peer review is the wrong tool

Not every disputed authorization deserves physician-to-physician review. A process becomes inefficient when clinicians are asked to resolve problems that are fundamentally administrative. Examples include an incorrect member identifier, a missing referral number, a network-status discrepancy, an authorization routed to the wrong benefit administrator, a duplicate request, or a billing-code mismatch that does not require clinical judgment. Those issues should reach trained operational staff with authority to correct them rather than consume scarce physician time.

The same principle applies when the dispute is purely contractual. If a benefit expressly excludes a service and no medical-necessity exception or other legal protection is available, a peer-to-peer conversation cannot transform the benefit by clinical persuasion. The appropriate route may be a coverage appeal, contractual interpretation, regulator complaint, employer-benefit review, or another process depending on the plan. Sending every disagreement to a medical director can obscure the true reason for noncoverage and create the appearance that a clinical judgment caused a decision that was actually contractual.

There are also situations in which a formal appeal should take priority. When the adverse notice reflects a contested interpretation of governing law, an experimental-treatment dispute, repeated use of an allegedly unlawful criterion, or a decision that requires external review, preserving the formal record may be more important than an informal call. A peer-to-peer conversation can still be attempted if it does not compromise deadlines, but it should not replace the process that can generate an appealable written determination.

Finally, clinicians should not be forced into peer-to-peer review merely to learn why the request was denied. The reason should be communicated through the required notice and, where applicable, the specific-reason requirements of CMS-0057-F or other law. Direct clinical conversation is most valuable after the parties know what they disagree about. Using it as a substitute for a clear written reason reverses the sequence and creates unnecessary burden.

A well-designed program therefore has both an inclusion rule and an exclusion rule. It identifies which disputes genuinely benefit from clinician judgment and which should be resolved through administrative correction, formal appeal, or another established channel. That discipline protects physician time, makes metrics more meaningful, and allows peer-to-peer review to serve the purpose its name suggests: focused professional discussion about a real clinical coverage question.

Sources and Authorities

Each source below was audited against the official publisher on August 9, 2026. Laws, proposed rules, and agency pages change; time-sensitive requirements should be checked against the current official source.

CMS Interoperability and Prior Authorization Final Rule, CMS-0057-F

CMS Prior Authorization API FAQ

CMS Electronic Prior Authorization

CMS-0057-F implementation and guidance page

CMS 2026 Interoperability Standards and Prior Authorization for Drugs Proposed Rule

California Department of Managed Health Care — File a Complaint

California Department of Insurance — Independent Medical Review

Related Articles

• Prior Authorization: A Patient and Physician Guide
• FHIR APIs and Coverage Decisions
• Algorithmic Prior Authorization and Human Accountability